Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DxS working on Erbitux companion diagnostic

This article was originally published in The Gray Sheet

Executive Summary

Molecular diagnostics firm DxS will develop a K-RAS gene mutation test for use as a companion diagnostic for the metastatic colorectal cancer drug Erbitux (cetuximab) under a collaboration with the drug's developers, Bristol-Myers Squibb and Eli Lilly/ImClone, announced Sept. 2. If approved by FDA, the DxS TheraScreen test would be used to determine which potential Erbitux patients have K-RAS mutations in codons 12 and 13. The use of monoclonal antibody epidermal growth factor receptor (EGFR) inhibitors like Erbitux is not recommended for the treatment of colorectal cancer with K-RAS mutations in codon 12 or 13, DxS notes. DxS inked a similar deal with Amgen for its colorectal cancer drug Vectibix (panitumumab) last December (1"The Gray Sheet" Dec. 8, 2008)

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts